Pharmacology of β-L-thymidine and β-L-2′-deoxycytidine in HepG2 cells and primary human hepatocytes:: Relevance to chemotherapeutic efficacy against hepatitis B virus

被引:43
|
作者
Hernandez-Santiago, B
Placidi, L
Cretton-Scott, E
Faraj, A
Bridges, EG
Bryant, ML
Rodriguez-Orengo, J
Imbach, JL
Gosselin, G
Pierra, C
Dukhan, D
Sommadossi, JP
机构
[1] Novirio Pharmaceut Inc, Cambridge, MA 02140 USA
[2] Univ Alabama, Dept Pharmacol, Birmingham, AL 35294 USA
[3] SARL, Novirio Pharmaceut, Montpellier, France
[4] Univ Montpellier 2, UMR CNRS UM II 5625, Lab Chim Organ Biomol Synthese, Montpellier, France
[5] Univ Puerto Rico, Dept Chem, San Juan, PR 00936 USA
关键词
D O I
10.1128/AAC.46.6.1728-1733.2002
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
beta-L-Thymidine (L-dT) and beta-L-2'-deoxycytidine (L-dC) are potent and highly specific inhibitors of hepatitis B virus (HBV) replication both in vivo and in vitro (50% effective concentrations, 0.19 to 0.24 muM in 2.2.15 cells). The intracellular metabolisms of L-dT and L-dC were investigated in HepG2 cells and primary cultured human hepatocytes. L-dT and L-dC were extensively phosphorylated in both cell types, with the 5'-triphosphate derivative being the predominant metabolite. In HepG2 cells, the 5'-triphosphate levels were 27.7 +/- 12.1 and 72.4 +/- 1.8 pmol/10(6) cells for L-dT and L-dC, respectively. In primary human hepatocytes, the 5'-triphosphate levels were 16.5 +/- 9.8 and 90.1 +/- 36.4 pmol/10(6) cells for L-dT and L-dC, respectively. Furthermore, a choline derivative of L-dCDP was detected at concentrations of 15.8 +/- 1.8 and 25.6 +/- 0.1 pmol/10(6) cells in human hepatocytes and HepG2 cells, respectively. In HepG2 cells exposed to L-dC, the 5'-monophosphate and 5'-triphosphate derivatives of beta-L-2'-deoxyuridine (L-dUMP and L-dUTP, respectively) were also observed, reaching intracellular concentrations of 6.7 +/- 0.4 and 18.2 +/- 1.0 pmol/10(6) cells, respectively. In human hepatocytes, L-dUMP and L-dUTP were detected at concentrations of 5.7 +/- 2.4 and 43.5 +/- 26.8 pmol/10(6) cells, respectively. It is likely that deamination of L-dCMP by deoxycytidylate deaminase leads to the formation of L-dUMP, as the parent compound, L-dC, was not a substrate for deoxycytidine deaminase. The intracellular half-lives of L-dTTP, L-dCTP, and L-dUTP were at least 15 h, with intracellular concentrations of each metabolite remaining above their respective 50% inhibitory concentrations for the woodchuck hepatitis virus DNA polymerase for as long as 24 h after removal of the drug from cell cultures. Exposure of HepG2 cells to L-dT in combination with L-dC led to concentrations of the activated metabolites similar to those achieved with either agent alone. These results suggest that the potent anti-HBV activities of L-dT and L-dC are associated with their extensive phosphorylation.
引用
收藏
页码:1728 / 1733
页数:6
相关论文
共 50 条
  • [1] Cellular pharmacology of β-L-thymidine (L-dT, NV-02B) and β-L-2′-deoxycytidine (L-dC, NV-02C) in HepG2 cells and primary rat, monkey and human hepatocytes.
    Placidi, L
    Hernández, B
    Cretton-Scott, E
    Faraj, A
    Bryant, M
    Imbach, JL
    Gosselin, G
    Pierra, C
    Dukhan, D
    Sommadossi, JP
    ANTIVIRAL RESEARCH, 2000, 46 (01) : A56 - A56
  • [2] β-L-thymidine and β-L-2′-deoxycytidine are potent, selective and specific anti-hepatitis B virus agents.
    Faraj, A
    Loi, AG
    Cui, L
    Xie, MY
    Bryant, M
    Bridges, EG
    Joudawis, A
    Pierra, C
    Dukhan, D
    Gosselin, G
    Imbach, JL
    Schinazi, RF
    Pai, B
    Korba, B
    Marion, P
    Sommadossi, JP
    ANTIVIRAL RESEARCH, 2000, 46 (01) : A62 - A62
  • [3] Antiviral activity of β-L-thymidine and β-L-2′-deoxycytidine in the woodchuck model of chronic hepatitis B infection.
    Bridges, EG
    Juodawikis, A
    Faraj, A
    Tennant, B
    Korba, B
    Schinazi, RF
    Barnett, T
    Gosselin, G
    Imbach, JL
    Pierra, C
    Dukhan, D
    Sommadossi, JP
    Bryant, M
    ANTIVIRAL RESEARCH, 2000, 46 (01) : A62 - A62
  • [4] Cellular Pharmacology of the Anti-Hepatitis B Virus Agent β-L-2′,3′-Didehydro-2′,3′-Dideoxy-N4-Hydroxycytidine: Relevance for Activation in HepG2 Cells
    Matthes, E.
    Buenger, H.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (01) : 341 - 345
  • [5] A New Cell Culture System for Infection with Hepatitis B Virus that Fuses HepG2 Cells with Primary Human Hepatocytes
    Jiang, Y.
    Wang, A. H.
    Shao, L. H.
    Wang, G.
    Yao, Y. Y.
    Sai, L. T.
    Chen, F. Z.
    Zheng, F.
    Li, Y.
    Ma, L. X.
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2009, 37 (03) : 650 - 661
  • [6] Hepatitis B virus infection and replication in a new cell culture system established by fusing HepG2 cells with primary human hepatocytes
    Sai, Lin-Tao
    Yao, Yong-Yuan
    Guan, Yan-Yan
    Shao, Li-Hua
    Ma, Rui-Ping
    Ma, Li-Xian
    JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION, 2016, 49 (04) : 471 - 476
  • [7] Hepatitis B virus replication in human HepG2 cells mediated by hepatitis B virus recombinant Baculovirus
    Delaney, WE
    Isom, HC
    HEPATOLOGY, 1998, 28 (04) : 1134 - 1146
  • [8] Phase II enzyme levels in HepG2 cells and cryopreserved primary human hepatocytes and their induction in HepG2 cells
    Westerink, Walter M. A.
    Schoonen, Willem G. E. J.
    TOXICOLOGY IN VITRO, 2007, 21 (08) : 1592 - 1602
  • [9] INVITRO INFECTION OF HUMAN HEPATOMA (HEPG2) CELLS WITH HEPATITIS-B VIRUS
    BCHINI, R
    CAPEL, F
    DAUGUET, C
    DUBANCHET, S
    PETIT, MA
    JOURNAL OF VIROLOGY, 1990, 64 (06) : 3025 - 3032
  • [10] ROSIGLITAZONE SUPPRESSES THE REPLICATION OF HEPATITIS B VIRUS IN HEPG2 CELLS
    Wakui, Yuta
    Inoue, Jun
    Ueno, Yoshiyuki
    Obara, Noriyuki
    Tamai, Keiichi
    Kakazu, Eiji
    Kondo, Yasuteru
    Shiina, Masaaki
    Yamagiwa, Yoko
    Fukushima, Koji
    Shimosegawa, Tooru
    HEPATOLOGY, 2009, 50 (04) : 515A - 515A